Today LightOx Ltd, a North East based company announces the appointment of two new Non-Executive Directors to its board. Mr Paul Lelieveld and Dr Frans van Dalen have joined the LightOx team and will support the development of new light-activated drugs and fluorescent probes being produced at the company. The two appointments bring a wealth of knowledge in the pharmaceutical development and regulatory pathways as well as the investment community in this area.
Further to this LightOx announces that it has successfully closed its current funding round with Dutch Biopharma specialists Meneldor acting as the lead. The investment will help the commercialisation of LightOx Probes for use in research markets, and the development of the new drugs being developed by the team for Head & Neck, and skin cancers.
Dr Sam Whitehouse, LightOx CEO says “We are delighted to welcome Paul and Frans to the team. Their wealth of experience will help us to accelerate our activities in both commercialising our LightOx Probes to a global customer base, and our development of new therapeutics which are activated by light. We look forward to a long and productive future with our new NEDs.”
Mr Paul Lelieveld, Non-Executive Director “We are pleased to announce our investment in LightOx Ltd. We very much look forward to work with the highly experienced management team and together bring multiple LightOxbased medicines to patients in the future.”
Biographies Paul’s experience spans more than 25 years in Business & strategy development, management of technology and investments companies; Paul has successfully led investment rounds in several companies and invested for multiple funds.
Frans’ experience spans 30 years in the biopharmaceutical field. He has previously held management positions in Strategic Program Development, QA / QP, Project Management, R&D and Regulatory Affairs. With 25 years as one of the partners that build the Synthon Holding; he is an expert in R& D, Regulatory Affairs, manufacturing and commercialization of generic medicines, biosimilars and New Biological Entities.